We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+9.38%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$162M
AUM Growth
+$43M
Cap. Flow
+$46.5M
Cap. Flow %
28.77%
Top 10 Hldgs %
56.19%
Holding
71
New
20
Increased
17
Reduced
10
Closed
20

Top Buys

Rank Stock Value
1
AGTC
Applied Genetic Technologies Corporation
AGTC
+$14.3M
2
VCYT icon
Veracyte
VCYT
+$7.86M
3
SPNC
Spectranetics Corp
SPNC
+$6.98M
4
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$3.6M
5
ASND icon
Ascendis Pharma A/S
ASND
+$3.38M

Top Sells

Rank Stock Value
1
CEMP
Cempra, Inc.
CEMP
+$5.49M
2
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$3.74M
3
INSM icon
Insmed
INSM
+$3.12M
4
FOLD
Amicus Therapeutics
FOLD
+$2.28M
5
CORV
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
+$2.2M

Sector Composition

Rank Sector Weight
1 Healthcare 81.09%
2 Consumer Discretionary 1.98%
3 Industrials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANGO icon
51
AngioDynamics
ANGO
$627M
– –
-10,000
Closed -$178K
CERS icon
52
Cerus
CERS
$433M
– –
-100,000
Closed -$417K
EXEL icon
53
CALL
Exelixis
EXEL
$13.8B
– –
-329,000
Closed -$846K
INSM icon
54
Insmed
INSM
$21.3B
– –
-150,000
Closed -$3.12M
OFIX icon
55
Orthofix Medical
OFIX
$496M
– –
-60,000
Closed -$2.15M
PODD icon
56
Insulet
PODD
$11.8B
– –
-62,265
Closed -$2.08M
SAGE
57
DELISTED
Sage Therapeutics
SAGE
– –
-8,000
Closed -$402K
SPY icon
58
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$806B
– –
-10,000
Closed -$2.06M
TXMD icon
59
TherapeuticsMD
TXMD
$23.6M
– –
-378
Closed -$114K
MRNS
60
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-9,027
Closed -$325K
BLCM
61
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-4,399
Closed -$1.02M
SRNE
62
CALL
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-80,000
Closed -$925K
CORV
63
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
– –
-237,600
Closed -$2.2M
AVEO
64
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-59,387
Closed -$861K
NXTM
65
DELISTED
NxStage Medical Inc.
NXTM
– –
-53,665
Closed -$928K
RXDX
66
DELISTED
Ignyta, Inc.
RXDX
– –
-100,000
Closed -$995K
WINT
67
DELISTED
Windtree Therapeutics Inc
WINT
– –
-28,082
Closed -$468K
PTX
68
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
– –
-35,000
Closed -$3.74M
DYAX
69
CALL
DELISTED
DYAX CORPORATION
DYAX
– –
-50,000
Closed -$838K
GNVC
70
DELISTED
GenVec, Inc.
GNVC
– –
-15,451
Closed -$456K
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2015 Portfolio in Review

As of Q2 2015, Acuta Capital Partners held 71 positions worth $162M, up 36% from $119M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Acuta Capital Partners deployed $46.5M of net new capital in Q2 2015, opening 20 new positions and adding to 17 existing holdings. Its largest new stake was Applied Genetic Technologies Corporation: 748,000 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 80% a quarter earlier, followed by Consumer Discretionary and Industrials.

On the sell side, the largest reduction was Cempra, Inc., an estimated $5.49M trimmed.

  • Acuta Capital Partners's largest Q2 2015 buy was Applied Genetic Technologies Corporation: 748,000 shares worth $11.5M.
  • Acuta Capital Partners added most to Ascendis Pharma A/S in Q2 2015, an estimated $3.38M increase.
  • Acuta Capital Partners's biggest Q2 2015 reduction was Cempra, Inc., cutting an estimated $5.49M.
  • Acuta Capital Partners fully exited Pernix Therapeutics Holdings, Inc. in Q2 2015, selling an estimated $3.74M.
  • Acuta Capital Partners's ten largest holdings make up 56% of its $162M portfolio in Q2 2015.
  • Acuta Capital Partners opened 20 new positions and closed 20 in Q2 2015.
  • Acuta Capital Partners's portfolio value rose 36% quarter-over-quarter to $162M.

Based on Acuta Capital Partners's 13F filing for Q2 2015, filed 14 Aug 2015.